Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II placebo-controlled, randomized, observer-blind clinical trial to evaluate safety, tolerability, and immunogenicity of Covigenix VAX-001 in healthy adults 18 years and older

Next Previous
Trial Profile

A Phase II placebo-controlled, randomized, observer-blind clinical trial to evaluate safety, tolerability, and immunogenicity of Covigenix VAX-001 in healthy adults 18 years and older

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Covigenix VAX 001 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Entos Pharmaceuticals

Most Recent Events

  • 02 Sep 2021 According to an Entos Pharmaceuticals media release, South African Health Products Regulatory Authority (SAHPRA) approved Phase 2 study of Covigenix VAX-001
  • 02 Sep 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top